CLNN earnings analysis
What we found in CLNN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided extract does not contain the June 30, 2026 income statement, balance sheet, cash-flow statement, or segment disclosures, so current-period revenue, margins, EPS, liquidity, debt, inventory, receivables and free cash flow cannot be quantified. The principal disclosed development is that controls remained ineffective as of June 30, 2026, with material weaknesses spanning the control environment, accounting controls and IT general controls. Remediation continued during 2026, but the unresolved weaknesses represent a significant financial-reporting risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Internal-control remediation continues
- Management stated that remediation activities continued during 2026, including plans to add technical accounting resources and continue using external consultants until sufficient resources are available.
- No material legal proceedings reported
- The filing reported no material pending legal proceedings as of June 30, 2026.
- No insider trading arrangements reported
- No officers or directors adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material weaknesses remain unresolved
- As of June 30, 2026, management concluded that disclosure controls and procedures were not effective because of material weaknesses in the control environment, control activities, and information and communication.
- IT control deficiencies create reporting risk
- The filing identifies four IT general-control areas requiring improvement: user access, program change management, computer operations and backup monitoring, and program development testing and approval. Each deficiency could result in a material misstatement that is not timely prevented or detected.
- Existing 10-K risks remain applicable
- The company stated that there had been no material changes to its risk factors since the 2025 Form 10-K filed March 17, 2026; therefore, the previously disclosed risks remain applicable.
What they said about what is next.
The provided 10-Q extract does not include quantitative revenue or EPS guidance. No explicit outlook was identified.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Clene Inc. for Q1 2026 reported a significant decline in revenue and continued operating losses, with total revenue decreasing 81% to $5 million from the previous year. The company incurred a net loss of $8.1 million…
- 10-K · March 17, 2026
- Clene positions itself as a first-mover developer of clean-surfaced nanocrystal (CSN®) therapeutics led by lead asset CNM‑Au8 for ALS, MS and PD, and supplements/dietary products via its dOrbital/4Life relationships.…
- 10-Q · August 14, 2025
- Clene reported a dramatic revenue decline to $27,000 in Q2 2025 and a quarterly net loss of $7.419 million (EPS $(0.78)), driven by minimal product/royalty sales and continued R&D and G&A spend. Management generated…
- 10-Q · May 7, 2025
- Clene reported total revenue of $81,000 for the three months ended March 31, 2025, up $8,000 from $73,000 in Q1 2024. Net loss narrowed sharply to $(751,000) (EPS $(0.09)) from $(11,080,000) (EPS $(1.73)) in the…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CLNN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever